The value of Interferon β in multiple sclerosis and novel opportunities for its anti-viral activity: a narrative literature review

The value of Interferon β in multiple sclerosis and novel opportunities for its anti-viral activity: a narrative literature review

Interferon-beta (IFN-β) for Multiple Sclerosis (MS) is turning 30. The COVID-19 pandemic rejuvenated the interest in interferon biology in health and disease, opening translational opportunities beyond neuroinflammation. The antiviral properties of this molecule are in accord with the hypothesis of...

Full description

Bibliographic Details
Main Authors:	Gianmarco Bellucci, Angela Albanese, Caterina Rizzi, Virginia Rinaldi, Marco Salvetti, Giovanni Ristori
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-06-01
Series:	Frontiers in Immunology
Subjects:	multiple Sclerosis interferon β SARS-CoV-2 Epstein-Barr virus immune cells
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1161849/full

Similar Items

Interferon Antagonism of Epstein–Barr Virus Tegument Proteins
by: Wai-Yan Lui, et al.
Published: (2020-06-01)

IN VITRO CELLULAR RESPONSE TO INTERFERON-α2 IN CHILDREN WITH INFECTIOUS MONONUCLEOSIS CAUSED BY EPSTEIN-BARR VIRUS
by: L. M. Kurtasova, et al.
Published: (2016-04-01)

Markers of Epstein-Barr Virus Infection in Patients with Multiple Sclerosis
by: Cyril Debuysschere, et al.
Published: (2023-05-01)

THE PERIPHERAL BLOOD LEUKOCYTES SUSCEPTIBILITY TO INTERFERON-α2 IN VITRO CHANGE AMONGST CHILDREN WITH INFECTIOUS MONONUCLEOSIS
by: L. M. Kurtasova, et al.
Published: (2017-03-01)

Adoptive T‐cell therapy targeting Epstein–Barr virus as a treatment for multiple sclerosis
by: Corey Smith, et al.
Published: (2023-01-01)

INFLUENCE OF INGARON ON THE DYNAMICS OF INTERFERON-α AND -γ PRODUCTION AND ON THE MANIFESTATION OF CLINICAL SYMPTOMS IN PATIENTS WITH CHRONIC VIRUS EРSTHTEIN-BARR INFECTION
by: I. A. Rakityanskaya, et al.
Published: (2019-02-01)

CNS inflammatory demyelinating events after COVID-19 vaccines: A case series and systematic review
by: Virginia Rinaldi, et al.
Published: (2022-12-01)

INFLUENCE OF CYCLOFERON ON THE CELLULAR SUSCEPTIBILITY TO INTERFERON-α2 IN VITRO IN PATIENTS WITH INFECTIOUS MONONUCLEOSIS CAUSED BY EPSTEIN– BARR VIRUS
by: L. M. Kurtasova, et al.
Published: (2018-12-01)

Dimethyl Fumarate Treatment Reduces the Amount but Not the Avidity of the Epstein–Barr Virus Capsid-Antigen-Specific Antibody Response in Multiple Sclerosis: A Pilot Study
by: Massimiliano Castellazzi, et al.
Published: (2023-01-01)

Editorial: Environmental factors influencing the immune functions during multiple sclerosis
by: Joost Smolders, et al.
Published: (2023-01-01)

Multiple Sclerosis Pathogenesis: Possible Interplay between Vitamin D Status and Epstein Barr Virus Infection
by: Giulia Bivona, et al.
Published: (2023-01-01)

Plasma interferon-γ concentration: a potential biomarker of disease activity of systemic chronic active Epstein-Barr virus infection
by: Yu Uemura, et al.
Published: (2022-09-01)

the role of interferon - gamma( IFN-Y) In infectious mononucleosis like syndrome
by: Jabbar R.Z. AL-Autabbi
Published: (2007-10-01)

Roadmap for understanding mechanisms on how Epstein–Barr virus triggers multiple sclerosis and for translating these discoveries in clinical trials
by: Tobias V Lanz, et al.
Published: (2023-01-01)

Antibody Content against Epstein–Barr Virus in Blood Extracellular Vesicles Correlates with Disease Activity and Brain Volume in Patients with Relapsing–Remitting Multiple Sclerosis
by: Mireya Fernández-Fournier, et al.
Published: (2023-09-01)

A Case of Double Standard: Sex Differences in Multiple Sclerosis Risk Factors
by: Benedetta Angeloni, et al.
Published: (2021-04-01)

Mimicking the brain: Epstein-Barr virus and foreign agents as drivers of neuroimmune attack in multiple sclerosis
by: Olivia G. Thomas, et al.
Published: (2023-11-01)

Tonsillectomy in children with PFAPA-syndrome and Epstein-Barr viral infection
by: S. A. Levytska, et al.
Published: (2017-03-01)

From bedside to bench: how existing therapies inform the relationship between Epstein–Barr virus and multiple sclerosis
by: Zoe Dyer, et al.
Published: (2023-01-01)

An Absence of Epstein–Barr Virus Reactivation and Associations with Disease Activity in People with Multiple Sclerosis Undergoing Therapeutic Hookworm Vaccination
by: Peter A. C. Maple, et al.
Published: (2020-08-01)

Interferon-regulating activity of the CelAgrip drug and its influence on the formation of reactive oxygen species and expression of innate immunity genes in Burkitt’s lymphome cell cultures
by: Alexander N. Narovlyansky, et al.
Published: (2020-05-01)

MAIT Cells and Microbiota in Multiple Sclerosis and Other Autoimmune Diseases
by: Rosella Mechelli, et al.
Published: (2021-05-01)

Prevalence of Epstein-Barr Viral DNA among children at a single hospital in Suzhou, China
by: Ting Shi, et al.
Published: (2022-03-01)

Epstein–Barr virus and multiple sclerosis: moving from questions of association to questions of mechanism
by: Olivia G Thomas, et al.
Published: (2023-01-01)

Cytomegalovirus and Epstein–Barr Virus Associations with Neurological Diseases and the Need for Vaccine Development
by: Peter A. C. Maple
Published: (2020-01-01)

THE MODERN CONCEPTIONS ABOUT IMMUNOPATHOGENESIS OF INFECTION CAUSED BY THE EPSTEIN–BARR VIRUS
by: T. V. Goreiko, et al.
Published: (2014-06-01)

Diagnóstico diferencial de virus hepatótropos y no hepatótropos en pacientes atendidos en el Laboratorio Regional de Referencia Virológica. Maracaibo-Venezuela, año 2007
by: Costa-León Luciana, et al.
Published: (2010-06-01)

Thrombotic Microangiopathy in Interferon‐beta‐Treated Multiple Sclerosis Patient
by: Masoud Mohammad Malekzadeh, et al.
Published: (2020-06-01)

Interferon-beta for relapsing-remitting multiple sclerosis: a systematic review
by: Dian HE, et al.
Published: (2014-09-01)

Investigating the Occurrence of Femoral Head Avascular Necrosis in Patient with Multiple Sclerosis Treated with Interferon-Beta
by: Pegah Sadat Fatehi, et al.
Published: (2018-11-01)

Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective
by: Dejan Jakimovski, et al.
Published: (2020-01-01)

Transcriptional profile and Epstein-Barr virus infection status of laser-cut immune infiltrates from the brain of patients with progressive multiple sclerosis
by: Caterina Veroni, et al.
Published: (2018-01-01)

Epstein-Barr Virus-Induced Genes and Endogenous Retroviruses in Immortalized B Cells from Patients with Multiple Sclerosis
by: Lisa Wieland, et al.
Published: (2022-11-01)

A Case of Ulcerative Colitis Following Acute Hepatitis Induced by Epstein-Barr Virus Infection
by: Seung Hyun Oh, et al.
Published: (2016-08-01)

Soro-epidemiologia do virus de Epstein-Barr (VEB) The seroepidemiology of the Epstein-Barr vírus (EBV)
by: Claudio Sergio Pannuti
Published: (1981-02-01)

Adherence to interferon β treatment in Kosovan multiple sclerosis registry
by: Blerim Myftiu, et al.
Published: (2024-01-01)

Peripheral Vasculitis, Intermediate Uveitis and Interferon Use in Multiple Sclerosis
by: Haluk Esgin
Published: (2016-01-01)

Relationship between Epstein-Barr virus and cancer development
by: Medina-Ortega, Ángela Patricia, et al.
Published: (2017-04-01)

Insights into the interplay between Epstein‐Barr virus (EBV) and multiple sclerosis (MS): A state‐of‐the‐art review and implications for vaccine development
by: Mahtab Mohammadzamani, et al.
Published: (2024-02-01)

Epstein–Barr Virus and Human Endogenous Retrovirus in Japanese Patients with Autoimmune Demyelinating Disorders
by: Davide Cossu, et al.
Published: (2023-12-01)